RU2608957C2 - Клеточные и генные способы улучшения сердечной функции - Google Patents

Клеточные и генные способы улучшения сердечной функции Download PDF

Info

Publication number
RU2608957C2
RU2608957C2 RU2013157590A RU2013157590A RU2608957C2 RU 2608957 C2 RU2608957 C2 RU 2608957C2 RU 2013157590 A RU2013157590 A RU 2013157590A RU 2013157590 A RU2013157590 A RU 2013157590A RU 2608957 C2 RU2608957 C2 RU 2608957C2
Authority
RU
Russia
Prior art keywords
ctnc
cardiomyocytes
cardiac
heart
atp
Prior art date
Application number
RU2013157590A
Other languages
English (en)
Russian (ru)
Other versions
RU2013157590A (ru
Inventor
Майкл РЕНЬЕР
Майкл ЛАФЛАММ
Чарльз МЕРРИ
Ф. Стивен КОРТ
Скотт ЛАНДИ
Стефен Денисон ХОШКА
Джеффри С. ЧЭМБЕРЛЭЙН
Гай ОДОМ
Original Assignee
Юниверсити Оф Вашингтон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Вашингтон filed Critical Юниверсити Оф Вашингтон
Publication of RU2013157590A publication Critical patent/RU2013157590A/ru
Application granted granted Critical
Publication of RU2608957C2 publication Critical patent/RU2608957C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
    • C12Y117/04—Oxidoreductases acting on CH or CH2 groups (1.17) with a disulfide as acceptor (1.17.3)
    • C12Y117/04001—Ribonucleoside-diphosphate reductase (1.17.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
    • C12Y117/04—Oxidoreductases acting on CH or CH2 groups (1.17) with a disulfide as acceptor (1.17.3)
    • C12Y117/04002—Ribonucleoside-triphosphate reductase (1.17.4.2)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
RU2013157590A 2011-05-26 2012-05-29 Клеточные и генные способы улучшения сердечной функции RU2608957C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490450P 2011-05-26 2011-05-26
US61/490,450 2011-05-26
PCT/US2012/039897 WO2012162705A2 (en) 2011-05-26 2012-05-29 Cell and gene based methods to improve cardiac function

Publications (2)

Publication Number Publication Date
RU2013157590A RU2013157590A (ru) 2015-07-10
RU2608957C2 true RU2608957C2 (ru) 2017-01-27

Family

ID=47218136

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013157590A RU2608957C2 (ru) 2011-05-26 2012-05-29 Клеточные и генные способы улучшения сердечной функции

Country Status (10)

Country Link
US (1) US9868937B2 (enExample)
EP (1) EP2714709B1 (enExample)
JP (1) JP6162104B2 (enExample)
KR (1) KR20140035967A (enExample)
CN (1) CN103946230B (enExample)
AU (1) AU2012258525B2 (enExample)
BR (1) BR112013030209A2 (enExample)
CA (1) CA2837322C (enExample)
RU (1) RU2608957C2 (enExample)
WO (1) WO2012162705A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9868937B2 (en) 2011-05-26 2018-01-16 University Of Washington Cell and gene based methods to improve cardiac function

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792742A1 (en) 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
WO2015153357A1 (en) * 2014-03-29 2015-10-08 Beat Biotherapeutics Corp. Compositions and methods for improving cardiac function
WO2016115543A2 (en) * 2015-01-16 2016-07-21 University Of Washington Novel micro-dystrophins and related methods of use
CA2979229A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
EP3337892A2 (en) 2015-08-18 2018-06-27 Boston Scientific Scimed Inc. Methods for producing cardiomyocyte cells
JP6940920B2 (ja) 2017-02-04 2021-09-29 アナバイオス コーポレーション 医薬誘発性の変力作用および不整脈誘発のリスクを予測するためのシステムおよび方法
CN108913655B (zh) * 2018-07-16 2022-07-15 浙江大学 基于多能干细胞技术建立“人源性”心肌肥大模型的方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR20210102870A (ko) 2018-08-30 2021-08-20 테나야 테라퓨틱스, 인코포레이티드 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
US20200405824A1 (en) * 2019-06-26 2020-12-31 University Of Washington Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease
CN110384800B (zh) * 2019-07-19 2021-06-08 广东省实验动物监测所 LncRNA XLOC_075168在制备促进血管新生的药物中的应用
FI4103214T3 (fi) 2020-02-13 2026-07-03 Tenaya Therapeutics Inc Geeniterapian vektorit sydänsairauden hoitoon
US20240189481A1 (en) * 2021-04-06 2024-06-13 University Of Washington Non-contractile cardiomyocytes for cardiac repair
CA3240616A1 (en) * 2021-12-10 2023-06-15 Christopher Dean HERZOG Troponin c (tnnc1) gene therapy using aav vector
WO2025207745A1 (en) * 2024-03-27 2025-10-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of inducing dilated cardiomyopathy phenotype in cardiomyocytes and applications thereof
CN120758566B (zh) * 2025-09-10 2025-11-21 瓯江实验室 一种在心肌细胞中特异性过表达zer1的病毒载体的构建及在心衰治疗中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062940A2 (en) * 1998-05-30 1999-12-09 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
WO2002049714A2 (en) * 2000-12-21 2002-06-27 Medtronic, Inc. Electrically responsive promoter system
US6671558B1 (en) * 1997-11-07 2003-12-30 Medtronic, Inc. Method and system for myocardial infarction repair
WO2005094485A2 (en) * 2004-03-25 2005-10-13 Yun Yen Drug screening
EP1950301A2 (en) * 1990-10-17 2008-07-30 The Wellcome Foundation Limited Antibody for use in Therapy
RU2378375C2 (ru) * 2003-11-21 2010-01-10 Асубио Фарма Ко., Лтд. Способ пролиферации кардиомиоцитов

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02240440A (ja) 1989-03-14 1990-09-25 Shiigeru:Kk 慣性ダンパ
CN1159445C (zh) 1998-09-11 2004-07-28 加利福尼亚大学董事会 能在心脏中组织特异性表达的重组腺病毒
EP1139751A4 (en) * 1998-12-28 2003-03-19 Arch Dev Corp EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS
EP1509252A4 (en) * 2002-05-08 2006-08-16 Univ California METHOD AND COMPOSITIONS FOR CORRECTING HEART TRANSFER FAULTS
WO2004024867A2 (en) 2002-09-11 2004-03-25 University Of Florida Vigilant vector system
EP1654365A1 (en) 2003-08-11 2006-05-10 University Of South Florida Vigilant cells
DE102011018586A1 (de) 2011-04-26 2012-10-31 Oliver Müller Vektorsystem zur spezifischen Genexpression im Herzmuskel
CA2837322C (en) 2011-05-26 2023-03-21 University Of Washington Cell and gene based methods to improve cardiac function

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1950301A2 (en) * 1990-10-17 2008-07-30 The Wellcome Foundation Limited Antibody for use in Therapy
US6671558B1 (en) * 1997-11-07 2003-12-30 Medtronic, Inc. Method and system for myocardial infarction repair
WO1999062940A2 (en) * 1998-05-30 1999-12-09 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
WO2002049714A2 (en) * 2000-12-21 2002-06-27 Medtronic, Inc. Electrically responsive promoter system
US20030204206A1 (en) * 2000-12-21 2003-10-30 Medtronic, Inc. Electrically responsive promoter system
RU2378375C2 (ru) * 2003-11-21 2010-01-10 Асубио Фарма Ко., Лтд. Способ пролиферации кардиомиоцитов
WO2005094485A2 (en) * 2004-03-25 2005-10-13 Yun Yen Drug screening

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. REGIER et al, 2-Deoxy-ATP Enhances Contractility of Rat Cardiac Muscle, Circ Res. 2000, . *
M. REGIER et al, 2-Deoxy-ATP Enhances Contractility of Rat Cardiac Muscle, Circ Res. 2000, реферат. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9868937B2 (en) 2011-05-26 2018-01-16 University Of Washington Cell and gene based methods to improve cardiac function

Also Published As

Publication number Publication date
JP2014517694A (ja) 2014-07-24
BR112013030209A2 (pt) 2017-06-13
JP6162104B2 (ja) 2017-07-12
AU2012258525A1 (en) 2013-12-12
WO2012162705A3 (en) 2013-02-28
US20160186139A1 (en) 2016-06-30
US9868937B2 (en) 2018-01-16
RU2013157590A (ru) 2015-07-10
CA2837322A1 (en) 2012-11-29
EP2714709B1 (en) 2018-04-18
CN103946230A (zh) 2014-07-23
WO2012162705A2 (en) 2012-11-29
EP2714709A2 (en) 2014-04-09
EP2714709A4 (en) 2015-05-13
CN103946230B (zh) 2017-02-08
KR20140035967A (ko) 2014-03-24
AU2012258525B2 (en) 2017-02-23
CA2837322C (en) 2023-03-21

Similar Documents

Publication Publication Date Title
CN103946230B (zh) 改善心脏功能的基于细胞和基因的方法
Grueter et al. CaMKII, an emerging molecular driver for calcium homeostasis, arrhythmias, and cardiac dysfunction
Shang et al. Cardiac-specific VEGFB overexpression reduces lipoprotein lipase activity and improves insulin action in rat heart
US20110077702A1 (en) Means and Methods for Influencing Electrical Activity of Cells
JP2013510839A (ja) 治療方法およびスクリーニング方法
EP2105142A1 (en) Means and methods for influencing electrical activity of cells
WO1999004636A1 (en) Evaluation of, delivery of, and use of agents to treat heart disorders
Feest Engineering troponin C with altered Ca2+ binding properties to study mechanisms of enhanced contraction of cardiac muscle from healthy and infarcted hearts
Leone et al. Cardiac turnover and regeneration219c-kit-positive cardiac stem cells regulate physiological myocardial cell turnover and are not of bone marrow origin in the adult life
Bhupathy Sarcolipin a novel regulator of the cardiac sarcoplasmic reticulum calcium ATPase
Nowakowski Engineering the Cardiac Fuel Supply: Elevation of 2-deoxy-ATP for Myofilament-Targeted Treatment of Heart Failure
WO2015153357A1 (en) Compositions and methods for improving cardiac function
Rust Adenovirus-mediated myofilament gene transfer into cardiac myocytes: Effects on myocyte structure and function
Meiser et al. Young Investigators Competition251Mitofusin 2 controls calcium transmission between the SR and mitochondria and regulates the bioenergetic feedback response in cardiac myocytes
Robinson et al. 256Cardiomyopathy-causing mutations in cardiac thin filament regulatory proteins acutely affect Ca2+ buffering and Ca2+ dependant signalling in situ
Mioulane et al. 234Cardiotoxicity of chemotherapeutic agents assessed in human embryonic or induced pluripotent stem cell-derived cardiomyocytes
Paavola et al. 255PKD2 mutations lead to impaired calcium cycling in the heart and predispose to heart failure
Stapel et al. 252Cardiac STAT3 deficiency is a pre-disposition for heart failure in response to beta-adrenergic stimulation
Sbroggio et al. 250Melusin controls MAPK-ERK1/2 and PI3K-AKT pathways activation in the heart by forming specific signalosomes
Buckingham et al. Oral abstract session240Cardiogenesis: clonal relationships within the second myocardial cell lineage and the contribution of sub-lineages, via the second heart field, to the poles of the heart
Duerr et al. Signaling control of myocardial survival249Endocannabinoids and cannabinoid receptor CB2 act cardioprotective in a murine model of ischemic cardiomyopathy
Mias et al. 220Ephrin-B1 regulates cell cycle arrest in adult cardiomyocytes: impact on cardiac tissue regeneration
Schroen et al. 253Absence of microRNA-155 protects against adverse cardiac inflammation and hypertrophy during pressure overload and prevents heart failure
Egorova et al. New insights in mechanosensing225Lack of primary cilia primes shear-induced endothelial-to-mesenchymal transition
Tokar et al. 242Progressive changes in cardiomyocyte structure and beta-2 adrenergic receptors cAMP signaling localisation in a rat model of myocardial infarction

Legal Events

Date Code Title Description
HC9A Changing information about inventors
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180530